Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AtriCure (ATRC) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for AtriCure (ATRC) over the last 17 years, with Q3 2025 value amounting to $32.9 million.

  • AtriCure's Cost of Revenue rose 1311.95% to $32.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $130.2 million, marking a year-over-year increase of 1541.03%. This contributed to the annual value of $117.8 million for FY2024, which is 1912.31% up from last year.
  • Per AtriCure's latest filing, its Cost of Revenue stood at $32.9 million for Q3 2025, which was up 1311.95% from $34.7 million recorded in Q2 2025.
  • In the past 5 years, AtriCure's Cost of Revenue registered a high of $34.7 million during Q2 2025, and its lowest value of $14.7 million during Q1 2021.
  • For the 5-year period, AtriCure's Cost of Revenue averaged around $24.6 million, with its median value being $23.9 million (2023).
  • Over the last 5 years, AtriCure's Cost of Revenue had its largest YoY gain of 3134.4% in 2021, and its largest YoY loss of 274.74% in 2021.
  • Over the past 5 years, AtriCure's Cost of Revenue (Quarter) stood at $18.2 million in 2021, then grew by 25.89% to $22.9 million in 2022, then rose by 16.64% to $26.7 million in 2023, then rose by 18.45% to $31.7 million in 2024, then rose by 4.04% to $32.9 million in 2025.
  • Its Cost of Revenue was $32.9 million in Q3 2025, compared to $34.7 million in Q2 2025 and $31.0 million in Q1 2025.